Prexige Review Will Not Include FDA Arthritis Drugs Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis expects action later this year on lumiracoxib after resubmitting the application, the company tells “The Pink Sheet” DAILY.
You may also be interested in...
Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths
A decision to withdraw Novartis' Prexige (lumiracoxib) in Australia after two patients died from serious liver injury following treatment with the drug is likely to impact the outcome of FDA's decision on a pending NDA for the COX-2 inhibitor
Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths
Withdrawal of the COX-2 inhibitor in Australia following two deaths from liver injury is likely to impact the outcome of FDA’s review.
Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths
Withdrawal of the COX-2 inhibitor in Australia following two deaths from liver injury is likely to impact the outcome of FDA’s review.